Keloid Treatment Market to Reach a Valuation of US$ 4,414.6 Mn By 2027

According to the latest market report published by Future Market Insights titled‘Keloid Treatment Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027),’the global keloid treatment market is estimated to be worth US$ 3,145.8 Mn by 2017 end, and is expected to expand at a CAGR of 3.4% over the forecast period of 2017–2027 to reach a market valuation of US$ 4,414.6 Mn by the end of 2027.

Global Keloid Treatment Market: Dynamics

The global keloid treatment market growth is substantially driven by the rising prevalence of keloid scars as well as the development of multiple keloids. A growing consciousness among patients regarding their appearance is also driving the market of keloid treatment as keloid scars on the exposed body parts leads to ugly appearances. Other factors that are driving the growth in the keloid treatment market include increasing reimbursement for keloid therapies, formalisation of standard treatment guidelines for keloid and increasing use of combination therapies. Clinics and hospitals are focussing on the adoption of advanced therapy options. CryoShape is used to reduce the impact of keloid scar and recurrence rate. Sensus Healthcare has developed an advanced superficial radiation therapy device to impart better treatment with limited adverse reactions.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1313 

Global Keloid Treatment Market: Segmental Forecast

The global keloid treatment market is segmented based on treatment type, end user and region. On the basis of treatment type, the market has been segmented intoocclusive dressing, compression therapy, cryosurgery, excision, radiation therapy, laser therapy, interferon therapy, intralesional corticosteroid injection and others. Other treatment options include dermal fillers, topical creams, 5-fluorouracil, retinoic acid and imiquimod. Intralesional corticosteroid injection treatment segment dominates the global keloid treatment market as this procedure is considered the gold standard and is being used in combination with other therapies. Intralesional corticosteroid injection is expected to be the second most lucrative segment by treatment type, with a market attractiveness index of 2.1 during the forecast period.

Based on end user, the global keloid treatment market is segmented into hospitals, dermatology clinics, ambulatory surgical centres and others. Thehospitals segment is expected to remain dominant, as most of the radiation therapies and excision procedures are performed in hospitals. Hospitals is the largest segment by end user, which is estimated to represent US$ 1,164.7 Mn, or 37.0% share of the total market in 2017 and is projected to reach a market valuation of US$ 1,643.8 Mn, or 37.2% share of the total market by the end of 2027, expanding at a CAGR of 3.5% in terms of value.

Global Keloid Treatment Market: Regional Analysis

On the basis of region, the global keloid treatment market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan and the Middle East & Africa.

North America dominated the global keloid treatment market in 2016 and is expected to continue to dominate the global market throughout the forecast period. North America is the largest region in keloid treatment market, which is estimated to represent US$ 1,105.6 Mn, or 35.1% share of the total market in 2017 and is projected to reach a market valuation of US$ 1,549.6 Mn, or 35.1% of the total market by the end of 2027, expanding at CAGR of 3.4% in terms of value. Clinics in North America are opting advanced treatment therapies that can aid in reduced risk of recurrence.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1313 

Global Keloid Treatment Market: Vendor Analysis

Leading players in the global keloid treatment market are launching new portable and mobile radiation therapy devices and are offering better treatment options to patients. Companies are targeting dermatology clinics to market their devices, where patients are provided the first line of treatment for keloid. Some of the players operating in the global keloid treatment market who have been profiled in the report include Novartis AG, Sensus Healthcare, RXi Pharmaceuticals, Inc., Sonoma Pharmaceuticals, Inc., Perrigo Company plc, Bristol-Myers Squibb Company, Pacific World Corporation, Valeant Pharmaceuticals International, Inc., Revitol Corporation and Avita Medical Limited.

Continuous Peripheral Nerve Block Catheter Market will Exhibit a Steady 6.1% CAGR through 2027

Future Market Insights has delivered key insights and presented a revised forecast analysis on continuous peripheral nerve block catheters market in its new research study titled “Continuous Peripheral Nerve Block Catheter Market: Global Industry Analysis (2012-2016) and Forecast (2017-2027)”. Continuous peripheral nerve block catheter are increasingly being used for pain management in patients undergoing upper/lower extremity surgeries and patients suffering from trauma, owing to their advantages, such as meticulous precision and low-price. Continuous peripheral nerve block catheter are emerging as a credible alternative to opioids for pain management as ill-effects associated with opioids are very severe such as addiction to opioids

Global Continuous Peripheral Nerve Block Catheter Market: Forecast Highlights

The global continuous peripheral nerve block catheter market is anticipated to record a CAGR of 6.1% and the market is estimated to reach a value of US$ 742.7 Mn in 2027 from a valuation of around US$ 411 Mn in 2017.

Global Continuous Peripheral Nerve Block Catheter Market: Segmental Analysis

The market is segmented based on product type, insertion technique, indication, end users and regions. On the basis of product type, the market has been segmented into stimulating catheter system, non-stimulating catheter systems and over-the-needle catheter systems. Non-stimulating catheter systems segment dominated the global continuous peripheral nerve block catheter market in terms of value and volume in 2017. This segment is expected to continue its dominating streak throughout the forecast period.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1307

On the basis of insertion technique, the continuous peripheral nerve block catheter market has been segmented into nerve stimulation and ultrasound based insertion technique. Continuous peripheral nerve block catheter that uses ultrasound based insertion technique is expected to witness higher demand than devices that use nerve stimulation technique for catheter insertion. The ultrasound based insertion technique segment is projected to grow at a higher rate during the forecast period. However, the nerve stimulation based insertion technique segment is expected to show a higher market valuation.

On the basis of indication, the continuous peripheral nerve block catheter market has been segmented into trauma cases, upper extremity surgeries, lower extremity surgeries, pain management and other indications. Amongst these aforementioned segments, lower extremity surgeries segment is expected to witness higher revenue growth as compared to other segments over the forecast period and this segment is expected to show higher value CAGR throughout the period of assessment.

Key end-use sectors that generate the bulk of demand for continuous peripheral nerve block catheter can be broadly categorised into hospitals and ambulatory surgical centres. Among these, hospitals account for the largest revenue share of the market, owing to increasing number of hospitalisations for upper/lower extremity procedures carried out in hospitals. The hospital segment is a highly lucrative segment from an investment standpoint.

FMI’s report has segmented the global continuous peripheral nerve block catheter market on the basis of region into North America, Western Europe, Eastern Europe, Latin America, Asia Pacific Excluding Japan (APEJ), Middle East & Africa and Japan. This report assesses trends driving each market segment and offers analysis and insights about the potential of continuous peripheral nerve block catheter in specific regions. The North America region is the leading region in terms of global revenue share, followed by Western Europe and Japan. North America is estimated to dominate the continuous peripheral nerve block catheter market with maximum value share of the overall market by end of 2017. North America continuous peripheral nerve block catheter market increase at a CAGR of 6.5% through 2027. Presence of key regional players, strong distribution network, and developed healthcare infrastructure are the key factors driving the growth of the market in North America.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1307

Global Continuous Peripheral Nerve Block Catheter Market: Competitive Assessment

Some key players in the global continuous peripheral nerve block catheter market identified include B. Braun Melsungen AG, Teleflex Incorporated, Halyard Health, Inc., Epimed International Inc. and Pajunk GmbH.

Silent Scan Technology Market Greater Revenue Share by 2026

Adoption of silent scan technology continues to face major challenges, with high cost and a general lack of awareness being the key restraints, according to a new survey by Future Market Insights (FMI). The survey was conducted among respondents from 300 global healthcare facilities, spanning sectors in North America, Latin America, Western Europe, Eastern Europe, Middle East & Africa (MEA), Asia Pacific excluding Japan (APEJ), and Japan. Majority of the respondents in the survey were from the U.S., Canada, Germany, the U.K., the Netherlands, Belgium, Australia, Saudi Arabia and the U.A.E. 

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1623

Although 44% of responding healthcare facilities currently own an MRI machine with silent- or soft-scan technology, a majority of them were averse to installing one in the future. In addition to high cost of silent scan MRIs and lack of awareness, respondents cited absence of distribution facility and insufficiency of technology as other key factors for not having an MRI machine with silent scan technology.

“Silent scan technology is at a nascent stage globally, and although it serves as an effective model for reducing decibel levels, high cost continues to impede its widespread adoption,” said Vrishali Bhagwat, FMI consultant, and co-author of the report Silent Scan Technology Market - Emergence of Private Hospitals Segment as the Most Prominent End User is a Key Factor Driving Revenue Growth. “However, the future looks promising for the technology, as there’s an overall appreciation of the technology, especially among end-users in the private hospitals segment. As technology makes a headway and prices become competitive, adoption is expected to pick up globally.”

FMI’s survey found that adoption varied widely based on the type of healthcare setting. While hospitals are the leading end-users, respondents in private hospitals are more receptive towards the adoption of silent scan technology. Satisfaction with the overall effectiveness of silent scan MRIs is exceedingly high and there’s a sense of understanding that silent scan MRIs do what they promise—quiet, noise-free MRI scans. “Silent scan MRIs received a higher rating than their noisy counterparts from respondents, and this represents an underlying sentiment that the technology per se isn’t the root cause for slow adoption,” added Vrishali.

According to FMI’s market forecast report, silent scan installation base is anticipated to reach 1,815 units in 2016, up from 1,015 units in 2015. Silent scanners constituted 1% of total MRI machine installations in 2015, and owing to their positive reception among end-users, their adoption is expected to witness a steady increase during the forecast period.

Hospitals are the leading end-use segment in the global silent scan technology market, and are expected to account for nearly 50% volume share of the market in 2016. Regionally, North America and Asia Pacific excluding Japan (APEJ) are the two largest markets, accounting for over 50% share of the global market in terms of volume. The market in these two regions is dominated by the U.S. and China respectively.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1623

FMI’s report forecasts the global silent scan technology market to increase at a steady compound annual growth rate (CAGR) of 5.4% through 2026.

Urinary Tract Infection Treatment Market will Exhibit a Steady 2.1% CAGR through 2026

There has been an increasing prevalence of the urinary tract infection followed by which, greater emphasis is given to the urinary tract infection treatment for effective control of the incidents of the spreading urinary tract infections. The global analysis presented in the research study conducted by Future Market Insights (FMI), projects that the global urinary tract infection treatment market revenue is projected to grow at a CAGR of 2.1% during the forecast period from 2016 to 2026. The urinary tract infection treatment market is expected to account for over US$ 11,585.9 million by the end of 2026, owing to major changes projected by the market. Although the market projects a sluggish growth, the growing awareness of the urinary tract infection treatment further supported by favorable incentives and policies of reimbursements are expected to nurture the urinary tract infection treatment market throughout the period of assessment.

Regulatory requirements and declining investments in research are expected to lead the market towards a low CAGR. Complex clinical trials have resulted in a declining focus towards research and development by the major companies. Moreover, the sale of drugs and medication prescribed for the urinary tract infection treatment is seen declining as the patients suffering from urinary tract infection are symptom-free for an initial week or two, unlike the chronic diseases.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1340

Despite the setbacks, the growth of the urinary tract infection treatment market is expected to be predominantly triggered by the growing prevalence of urinary tract infections followed by the new medication and drugs prescribed for the urinary tract infection treatment. The stagnancy in the urinary tract infection treatment market is expected to be aided by new and improved drugs and medical breakthroughs that would redefine the future of the urinary tract infection treatment market. New improvements introduced to the urinary tract infection treatment market are expected to assist the market in effective recovery from the modest growth rate. Researchers have developed new antibiotics for fighting the urinary tract infections. The United States Food and Drug Administration (FDA) has approved the use of the antibiotic plazomicin for the treatment of complex urinary tract infections. Even though it is not a new antibiotic, plazomicin has been developed by the United States biotech Achaogen to treat infections.

Owing to the growing consumption of antibiotics in the BRICS countries, these regions are the most promising regions for the urinary tract infection treatment market. Amongst other regional markets stated in the research study, the APEJ market is projected to reach US$ 4,400.5 million in terms of revenue. As the consumption of antibiotics is highest in China and India owing to the rising disposable income in these countries, the APEJ region is expected to register a fastest growth rate of 2.4 percent in terms of market value over the forecast period.

The rising number of urinary tract infection patients across the globe owing to the urinary tract infection’s contribution to the second-largest patient pool in the world, there are a number of generic antibiotic drugs made available for the urinary tract infection treatment. This factor has changed the global scenario of the health-care and pharmaceutical industry. Major market players such as Cipla, GlaxoSmithKline, and Pfizer are seen investing in antibacterial discovery programs for an improved treatment of the urinary tract infection. 

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1340

Moreover, the major participants are focusing on contributing enhanced drugs to the urinary tract infection treatment market by involving in collaborations and focusing on extended research to cater to the unmet needs of the urinary tract infection patients. The market players such as Johnson & Johnson Private Ltd. are seen implementing expansion strategies for spreading their operations in leading markets such as China, India, and Brazil for growing their business as the sales are slow in matured markets in regions including the United States and Europe.

Digital Mobile X-Ray Devices Market Attractive Market Opportunities in the by 2026

Future Market Insights, in its latest research, delivers key insights on the factors impacting the global digital mobile X-ray device market. According to the report, demand for digital mobile X-ray devices will continue to be fuelled by applications in orthopaedic- and chest-imaging. These two end-use applications accounted for 60% revenue share of the market in 2016.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-990 

Key Driving Factors

• Increasing emphasis on diagnostic imaging services by various government bodies.
• Increasing geriatric population – according to WHO, global geriatric population will reach 2 billion by 2050
• Rising incidences of orthopaedic diseases and bone injuries – WHO estimates global prevalence of arthritis to between 0.3% and 1%
• Contractual agreements and acquisitions by manufacturers
• Increasing adoption of 3D medical imaging equipment, especially in the field of orthopaedics
• Increase in the number of free standing imaging centers

Key Restraints

• High cost of clinical trials and stringent regulations have remained longstanding challenges for manufacturers
• Lack of inadequate imaging infrastructure in developing countries. High cost associated with initial set up and installation has been identified as a major restraint
• Increasing pressure on the healthcare budget in the U.S. and rising awareness among patients about the potential health impact of radiation

By product type, mobile devices will continue to outsell handheld devices. In 2016, of the US$ 7.67 Bn worth of digital X-ray devices sold, 91.5% were mobile devices. However, owing to their small base size, demand for handheld digital mobile X-ray devices will grow at a higher CAGR than mobile devices.

Hospitals and radiology centers will continue to be the leading end-users of digital mobile X-ray devices globally. These two end-users collectively accounted for nearly 70% revenue share of the market in 2016. According to Future Market Insights’ research, these two end-use sectors will continue to account for the bulk of demand for digital mobile X-ray markets during the forecast period.

Region-wise Analysis and Forecast

• North America is the largest market for digital mobile X-rays globally. Demand for digital mobile X-ray devices in the region is fuelled by strong sales in the U.S.
• North America’s revenue share of the global market was nearly 32% in 2016. Owing to increasing demand in Asia Pacific excluding Japan (APEJ), Latin America, and Japan, North America will witness a slight dip in revenue share over the forecast period.
• APEJ is projected to be the fastest growing market for digital mobile X-ray devices globally. The market in the region is expected to grow on account of high volume demand from China and India.
• The Eastern Europe digital mobile X-ray market will witness slowest growth among all regions.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-990 

Competitive Landscape Analysis

Leading companies in the global digital mobile X-ray devices market are General Electric Healthcare Limited, Siemens AG, Esaote SpA, Hitachi Ltd., Koninklijke Philips N.V, Planmed OY, EOS Imaging, and Toshiba Medical Corporation. These leading companies are eyeing the lucrative APEJ market to capitalise on the growing opportunities. Future Market Insights maintains a positive outlook on the global digital mobile X-ray market, projecting it to grow at 7.1% CAGR through 2026.

Digital Breast Tomosynthesis (DBT) Equipment Market Promising Growth Opportunities over 2016 to 2026

Digital breast tomosynthesis (DBT) or 3-D mammography new installations (includes new equipment and 3-D upgradation) expected to reach 4,547 units in 2016, up from 4,061 units in 2015. In terms of revenues, the global digital breast tomosynthesis equipment market is expected to reach 1,007.6 Mn in 2016, witnessing a year-over-year growth of 13.7%. 

Limitations concerning the flat nature of images achieved through a 2-D full-field digital mammography (FFDM) is influencing end-users to adopt DBT equipment for diagnosis of breast cancers. Digital breast tomosynthesis enables radiologists to analyse abnormalities lucidly, helping improve detection rates while reducing callbacks. In the backdrop of these factors, demand for digital breast tomosynthesis equipment is witnessing an uptick, and the trend is expected to gain further momentum in the future.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1241

Sales of DBTs have remained quite robust in the US in the recent past, making North America the most lucrative market globally. The market in the region is largely dominated by Hologic, Inc. although GE and Siemens Healthineers have also registered their presence by launching innovative DBT products at competitive prices. Total DBT equipment revenues in North America were pegged at 472.8 Mn in 2015, with the U.S. accounting for bulk of revenue share. New equipment installation base in North America is expected to reach 2,327 in 2016, up from 2,066 in 2015.

In addition to North America, digital breast tomosynthesis sales are also growing steadily in Western Europe and APEJ. Revenues in Western Europe are anticipated to grow by 13.4% in 2016, whereas APEJ is expected to increase at 12.2%.

By end-users, hospitals account for higher demand for DBTs vis-à-vis diagnostic centres. Many hospitals are in the process of upgrading their existing mammography machines, owing to which demand for DBT equipment is growing at a steady rate. However, high costs, coupled with lack of awareness can impede adoption rates in both hospitals and diagnostic centres, and slow down the growth of the market globally. Installations of DBTs in hospitals totalled 3,020 in 2015, representing a market value worth 542.8 Mn.

Key players in the global digital breast tomosynthesis equipment market include Hologic Inc., GE Healthcare, Siemens Healthineers, Internazionale Medico Scientifica, Fujifilm, and Planmed Oy. The top 3 players - Hologic, Inc., GE Healthcare, and Siemens Healthineers collectively account for nearly 90% revenue share of the market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1241

Long-term Outlook: In terms of revenues, the global tomosynthesis equipment market is expected to increase at 13.9% CAGR during the forecast period 2016-2026. Total installations of DBT equipment are anticipated to reach 17,700 units.

Veterinary Vaccines Market to Gain a Stronghold by 2026

Demand for veterinary vaccines is witnessing an increase, as focus shifts from cure to prevention among farm- and pet- owners. The global pet humanisation trend is massively influencing demand for veterinary healthy products and services, and vaccines are riding on the coattails of this trend. The global veterinary vaccines market is anticipated to reach US$ 7.24 Bn in 2016, up from US$ 6.82 Bn in 2015.

Focus on improving food security and mitigating the spread of contagious diseases will continue to fuel demand for veterinary vaccines. Increase in foodborne and zoonotic diseases has adversely affected animal production in the recent past, owing to which emphasis on maintaining health and well-being of animals has gained prominence.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-409

On the basis of product type, attenuated live vaccines will continue to hold the leading revenue share, closely followed by inactivated vaccines. These two product segments accounted for nearly 47% revenue share of the market in 2015, and are expected to dominate global revenues in 2016 as well.

By disease type, foot and mouth disease and anaplasmosis are the two largest segments, collectively accounting for over US$ 2.1 Bn in revenues in 2015. Canine parvovirus is another key disease type, contributing significant revenues to the global market.

Veterinary clinics remain the most prominent distribution channel for veterinary vaccines, and accounted for nearly 40% revenue share of the market in 2015. Veterinary clinics sold US$ 2.74 Bn worth of veterinary vaccines in 2015, and this figure is expected to reach US$ 2.91 Bn in 2016.

By animal type, livestock animals accounted for bulk of the demand for veterinary vaccines in 2015, and the status quo is anticipated to remain unchanged in the future as well. Companion animals are further segmented into canine, avian, and feline, of which, canine segment accounted for the bulk of the revenues in 2015.

North America and Western Europe are the two largest markets for veterinary vaccines, collectively accounting for over 57% revenue share of the market in 2015. The market in North America is dominated by the U.S., which accounted for US$ 1.58 Bn in revenues in 2015. The Canada veterinary vaccines market is expected to surpass US$ 500 Mn in revenues in 2016. Outside of North America, Western Europe and Asia Pacific excluding Japan (APEJ) are the leading markets for veterinary vaccines.

Request for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-409

Key players in the global veterinary vaccines market include Merial, Zoetis, Elanco, Merck & Co. Inc, Boehringer Ingelheim GmbH (BIVI), Bayer Pharma AG, Ceva, Virbac, Diamond Animal Healthcare (Heska) and Indian Immunological Ltd.

India Static Compression Therapy Market Display Significant Growth by 2026

Strong demand from diabetics and geriatric population will continue to drive the growth of the India static compression therapy market in 2016. Demand will also grow on account of rising incidence of venous ulcers and other vein diseases. Compression bandages will continue to outsell compression garments, with the former accounting for a revenue share of over 60% in 2015. Overall, the India static compression therapy market is anticipated to rake in US$ 112 Mn in revenues in 2016.

Retail pharmacies will remain the dominant distribution channel, accounting for over 62% revenue share of the market in 2016. Valued at US$ 63 Mn in 2015, the retail pharmacies distribution channel will grow at 7.4% in terms of revenues to reach US$ 67.6 Mn in revenues in 2016.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-in-1680

Sales of compression therapy products and services are also growing through online channels. Online pharmacies are leveraging on offering doorstep delivery and competitive pricing to appeal to end-users. Sales through online pharmacies totalled US$ 39.9 Mn in 2015, and are expected to grow at 5.5% in 2016 to reach US$ 42.11 Mn.

Several players are anticipated to enter the India static compression therapy market, considering the steady growth that the market is currently experiencing. 3M Co., BSN Medical, Sigvaris AG, and Vissco Healthcare are some of the leading players in the India static compression therapy market.

The key players in the India static compression therapy market are focusing on establishing the distribution channels and creating awareness about the benefits of compression stocks among patients. Coban 2 Lite Compression Systems, Jobst, and Vissco Platinum are some of the well-known static compression therapy products available in the market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-in-1680

Long-term Outlook: The long-term outlook on the India static compression therapy market is positive, with total revenues expected to increase at a CAGR of 7.2% during the forecast period 2015-2025.

Anti-ageing Products, Services, and Devices Market Highly Favorable to the Growth Rate by 2018-2028

Anti-ageing products and services continue to witness steady growth, with global revenues poised to reach US$ 151.8 Bn in 2016, a growth of 7.7% over 2015. Generation X (born between early 60s to mid-70s) will continue to be the key consumer segment, with global demand from this consumer segment anticipated to reach US$ 66,099.3 Mn by the end of this year. The impact of the global ‘health and wellness’ trend has gained further momentum in 2016, with leading brands incorporating concepts of healthy ageing in their products and services.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1661 

Generation X will continue to remain the largest consumers of anti-ageing products and services, followed by baby boomers in terms of revenue share contribution. This demographic is expected to consume US$ 55.7 Bn worth of anti-ageing products and services in 2016-a y-o-y growth rate of 6.8%.

By products, anti-wrinkle products will continue to be the largest segment, contributing US$ 77.7 Bn to global revenues in 2016. Hair colour will remain the second largest segment, whereas dermal fillers will witness the highest y-o-y growth in 2016 over 2015. Hair restoration treatment will remain the most-after anti-ageing service, representing 43.8% revenue share on the basis of services.

By devices, radio frequency devices will maintain its top position in 2016 as well, representing a revenue share of 64.5%. This segment is expected to witness a year-over-year growth of 11.5% in 2016 and reach US$ 1.2 Bn in revenues. On the other hand, anti-cellulite treatment devices will witness the year-over-year growth in 2016, growing at 19.3% in 2016.

U.S.’s dominance of the global anti-ageing market will continue in 2016, and this in turn, will fuel the growth of the North America anti-ageing market. The region has been the hotbed of advances in cosmetology and dermatology, and has a high proliferation of anti-ageing products and services. The baby boomer and Generation X demographic in North America has been overly receptive to new products and services that mask the signs of ageing. These factors will continue to fuel the anti-ageing market in North America, with total revenues expected to reach US$ 51,987.4 Mn in 2016. The other lucrative markets for anti-ageing products and services are Europe and Asia Pacific.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1661 

Leading players in the global anti-ageing market include Allergan, Inc., L’Oreal SA, Solta Medical, Inc., Cynosure, Inc.

Specialty Active Pharmaceutical Ingredients (API) Market Will Target Emerging Markets by 2024

The global specialty active pharmaceutical ingredients (API) market is anticipated to record a year-over-year growth rate of 7.9% and reach a market value of US$ 119,513.1 Mn in 2016. Small molecules will continue to account for the leading market revenue share by product type, accounting for over two-thirds share in 2016.

Staggering increase in the manufacturing of HPAPI (high potency API) will continue to influence the adoption of API positively. Popularity of peptide-based drugs and the patent expiry of blockbuster branded drugs in the near future is also expected to boost the growth of the market. However, complex manufacturing guidelines and stringent regulatory processes will continue to pose challenges to widespread adoption.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1719 

By product type, growth of the small molecules segment will be positively impacted by increasing outsourcing of active pharmaceutical ingredients manufacturing from European to Asian countries. In addition, rising preference for HPAPI to treat cancer will play a crucial role in the growth of small molecule segment of the global specialty API market.

Based on the consumption pattern, the outsourced segment will continue to dominate market revenues, accounting for nearly 65% share in 2016. New pharmaceutical companies are increasingly entering the market with authorized and approved HPAPI, but lack of manufacturing facility infrastructure is providing an impetus to the outsourcing trend in terms of manufacturing. This factor is currently more pronounced in U.S.-based companies. Furthermore, the tendency of established pharmaceutical companies to curtail the operational and financial load of HPAPI manufacturing is anticipated to play a key role in elevating the outsourcing segment, boosting the growth of SMEs in the market.

FMI’s report has segmented the global specialty active pharmaceutical ingredient market on the basis of region into North America, Europe, and Rest of the World (ROW). The ROW is the leading region in terms of global revenue share, closely followed by Europe and North America. European API manufacturers are competing on the basis of high quality standards, advanced manufacturing installations, and high purity of intermediates (API), whereas ROW CMOs are focusing on bulk API manufacturing.

The key players in the small molecule active pharmaceutical ingredients segment include Johnson Matthey, Almac, and Siegfried Holding AG, which follow advanced manufacturing technology, premium promotion strategies, and provide a range of development and diagnostic services.

Notable companies in the peptide API segment are PolyPeptide Laboratories, Corden Pharma International GmbH (International Chemical Investors Group), Pepscan Holding, Provence Technologies Group, BCN Peptides S.A., and Senn Chemicals AG. They are characterized on the basis of expertise in development and manufacturing, strong client base, and activity in a wide range of industries.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1719 

Major HPAPI players in the market are Ash Stevens, Inc., Orion Corporation, Farmhispania Group, S.L., Olon S.p.A., and AmbioPharm, Inc., based on widespread market presence, government approvals, and strong distribution channels.

Platelet Rich Plasma (PRP) Market Set to Record Exponential Growth by 2026

The global platelet rich plasma (PRP) market is projected to witness a year-over-year growth rate of 11.8% in 2016 over 2015 to reach US$ 224.0 Mn in revenues. Increase in the number of patients suffering from orthopaedic injuries and widening application area of PRP in different surgeries is likely to catalyse the market the growth. Use of PRP therapy in treating sports injuries is also anticipated to boost the growth of the market.

By type, pure PRP is likely to dominate product segment in 2016 with the revenue share of about 65%. The segment is also forecast to dominate other application segments through the forecast period. This segment is estimated to witness a year-over-year growth of 11.4% to reach US$ 144.3 Mn in revenues in 2016. Pure PRF/Leukocyte rich PRF segment is projected to register impressive year-over-year growth of 15.5% in 2016.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1722 

By origin, autologous segment will continue to be the prominent segment in 2016, accounting for three fourth of total revenue generated in the year. This segment will witness a year-over-year growth of 11.0% to reach US$ 169.1 Mn in revenues in 2016. Autologous segment among other PRP origins is slated to reflect moderate market performance in 2016, is likely to lose market share to allogenic PRP over next four to five years. Allogenic segment is also projected to register an impressive year-over-year growth of nearly 15% in 2016.

Examining the PRP demand statistics from different surgeries clearly forebodes the dominance of orthopaedic surgery. Currently, orthopaedic surgery is the leading application segment accounting for a revenue share of over 35% in 2016.Orthopaedic surgery is followed by cosmetic surgery, which is estimated to be valued over US$ 50 Mn in 2016. Cosmetic surgery will continue to remain the second-largest application segment, with total revenues expected to reach US$ 59.6 Mn by 2016 end.

In terms of geography, North America, being the advanced market, characterized by early adopters of PRP based therapies. The market in North America is estimated to increase by 11.4% in 2016 to reach very close to US$ 120 Mn. Growth of the market in this region is supported by increasing number of cosmetic and orthopaedic surgeries. Moreover, the region is home to some of the most prominent players operating in the PRP market and hence awareness among patients is also high. Awareness among healthcare community as well as patients is also anticipated to fuel the growth of in North American market.

Adoption of PRP therapy in Asia Pacific is growing at a brisk pace, fuelled by the region’s status as an epicentre of medical tourism. The region has a high geriatric population, and adoption of PRP therapy has witnessed a surge in the recent past. The APAC plasma therapy market is anticipated to increase at a year-on-year growth rate of 16.1% in 2016 to reach US$ 40.5 Mn in revenues.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1722 

Key players operating in the global platelet rich plasma market are Harvest Technologies Corp., Biomet, Inc., Arthrex, Inc. and Arteriocyte Medical Systems, Inc. Dr. PRP America, Cesca Therapeutics, Inc., and Regen Lab SA.

Saudi Arabia Pharmaceutical Market CAGR Projected to Grow at 9.0% through 2026

The significant rise in lifestyle-related diseases and the developments in healthcare infrastructure are expected to influence the demand for pharmaceuticals in Saudi Arabia. In 2016, the Saudi Arabia pharmaceutical market is anticipated to procure value worth US$ 5,209.5 Mn at a y-o-y growth of 6.0 % over 2015. The mounting demand for branded drug products will continue to incite the growth of the Saudi Arabian pharmaceutical market in 2016.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gc-1733 

The demand for pharmaceuticals in Saudi Arabia is expected to register substantial growth owing to the increasing penetration of health insurance companies and the rising incidence rate of non-communicable diseases. Furthermore, the exceptional rise in the per capita income of Saudi Arabia is also expected to foster the demand for branded pharmaceutical drugs. Another key factor driving the growth of the pharmaceutical market in Saudi Arabia is the country’s strategic move to allow 100% FDI in the pharmaceuticals sector. Although, the shortage of profound indigenous research capacity in the pharmaceutical industry and the delayed registration of drug and medicine patents is expected to limit the expansion of the market in 2016 and beyond.

Based on the product type, the pharmaceutical market in Saudi Arabia is expected to witness an upsurge in the prescription-type branded drug products. In terms of market value, the branded drugs are estimated to reach US$ 2,760.8 Mn by 2016-end. The demand for generic drugs is projected to secure steady growth, attributing to the insisting promotion of generic drug adoption by healthcare insurance providers.

On the basis of the diseases, the pharmaceutical drugs used for treatment of cardiovascular diseases will continue exhibiting robust growth in 2016. The demand for cardiovascular medications will continue to surge due to the prominence of circulatory disorders in Saudi Arabia. Additionally, the rising prevalence of disorders related to body sugar levels is expected to make diabetes a rapidly growing disease-based sub-segment in the Saudi Arabia pharmaceutical market.

The pharmaceutical market in Saudi Arabia is also segmented on the basis of distribution channel, where retail pharmacies will continue to account for 80% market share compared to hospital pharmacies. The westernised modernisation of retail pharmacies in Saudi Arabia has led to the availability of a wide range drugs and medicinal products, thereby attaining a considerable growth in the retail pharmacy sub-segment in 2016 and further.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gc-1733 

The rising resource potential in Saudi Arabia is projected to positively reform the production environment for pharmaceutical manufacturers. In order to expand the market’s size, structuring alliances with well-established native companies is predicted to be a key strategy for global pharmaceutical leaders. The key players in the Saudi Arabia pharmaceutical market include Novartis AG, SPIMACO, Pfizer Inc., and Glaxosmithkline plc., Jamjoom Pharma,  and Tabuk Pharmaceutical Manufacturing Co. among others.

Industrial Microbiology Market to Significant Growth Foreseen by 2024

The global industrial microbiology market is expected to witness a y-o-y growth of 6.7% in 2016 over 2015 and reach US$ 9.46 Bn in revenues. North America will continue to be the most lucrative market, accounting for over 25% of the market share.

In addition to increase in food consumption, rising emphasis on industrial food safety is predicted to fuel market growth. Wide-ranging applications of industrial microbiology and biotechnology in various verticals, including agriculture, pharmaceuticals, and food & beverages are also expected to play a key role in driving the growth of the market. Consumer preference towards nutraceuticals, increasing automation, and strategic partnerships across the healthcare value chain are other key drivers for industrial microbiology market.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1743 

Manufacturing of sterile products specifically demands higher costs in order to maintain aseptic conditions, which remains an abiding challenge for the market. Growing demand for advanced technology is also expected to hamper market growth.

Apart from applications in fermentation of wine, beer, and cheese, the use of industrial microorganisms in syrup formulation is also gaining traction. Other influential trends include use in bioremediation processes, manufacturing of empty capsules, and preparation of genetically modified food products.

On the basis of product type, the global industrial microbiology market is segmented into reaction consumables, equipment & systems, and laboratory supply. While the reaction consumables segment is expected to dominate the market with over 60% of the total market share in 2016, equipment and systems segment’s revenue share will be over 25%. By test type, sterility testing and microbial limit testing are projected to collectively contribute around 60% to the total market share.

The pharmaceuticals & biotechnology segment will remain the largest end-use segment in the industrial microbiology segment, owing to rising novel drug development practices.

America will remain the largest and fastest growing market due to easier product approval processes. The U.S., a leading market for pharmaceuticals, will continue to dominate the North American market, accounting for over three-fourths revenue shares in 2016. Europe will maintain its position as the second largest market for industrial microbiology.

Thermo Fisher Scientific Inc., and bioMérieux SA remained the two largest players, accounting for a market share of 34.8% in 2015 (with respect to reaction consumables segment & reagent kits). Strong product portfolio, strategic R&D, strong market channels, prominent market presence, and sizeable presence in developing regions remain key strengths of these market leaders. Other leading players in the market include Merck KGaA, Qiagen, Sartorius AG, Bio-Rad Laboratories, Inc., and Becton, Dickinson and Company.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1743